IL2 and renal cell carcinoma: Atkins et al.,[14] reported that the level of CAIX in RCC tissues might also serve as a useful predictor of the response to IL-2 therapy and suggested that CAIX might maintain balanced pH in the tumor microenvironment, which might in turn be favorable for the maintenance of immune effector mechanisms.